for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Koninklijke Philips NV

PHG.AS

現在値

40.00EUR

変化

0.08(+0.19%)

出来高

4,136,221

本日のレンジ

39.97

 - 

40.67

52週レンジ

37.03

 - 

50.98

∙ 約20分前の相場を表示しています。

適時開示

Philips Cashes In About EUR 3 Bln Net From Domestic Appliances Sale

Sept 2 (Reuters) - Koninklijke Philips NV <PHG.AS>::PHILIPS COMPLETES SALE OF DOMESTIC APPLIANCES BUSINESS TO GLOBAL INVESTMENT FIRM HILLHOUSE INVESTMENT.RECEIVED CASH PROCEEDS AFTER TAX AND TRANSACTION-RELATED COSTS OF APPROXIMATELY EUR 3 BILLION..TRANSACTION VALUES DOMESTIC APPLIANCES AT AN ENTERPRISE VALUE OF APPROXIMATELY EUR 3.7 BILLION.TOTAL DEAL VALUE AMOUNTS TO APPROXIMATELY EUR 4.4 BILLION.

Philips Starts Repair, Replacement Program Of First-Generation Dreamstation Devices In U.S.

Sept 1 (Reuters) - Koninklijke Philips NV <PHG.AS>::PHILIPS STARTS REPAIR AND REPLACEMENT PROGRAM OF FIRST-GENERATION DREAMSTATION DEVICES IN THE US IN RELATION TO EARLIER ANNOUNCED RECALL NOTIFICATION*.PHILIPS RECEIVED AUTHORIZATION FROM US FOOD AND DRUG ADMINISTRATION (FDA) FOR REWORK OF AFFECTED FIRST-GENERATION DREAMSTATION DEVICES.REWORK CONSISTS OF REPLACEMENT OF PE-PUR SOUND ABATEMENT FOAM WITH A NEW MATERIAL. PHILIPS ANTICIPATES REWORK TO COMMENCE IN COURSE OF SEPTEMBER 2021.COMPANY HAS ALREADY STARTED REPLACING CERTAIN AFFECTED FIRST-GENERATION DREAMSTATION CPAP DEVICES IN US WITH DREAMSTATION 2 CPAP DEVICES.PHILIPS REMAINS IN DIALOGUE WITH FDA WITH RESPECT TO OTHER ASPECTS OF RECALL NOTIFICATION AND MITIGATION PLAN IN US.PHILIPS IS INITIATING REPAIR AND REPLACEMENT PROGRAMS IN OTHER COUNTRIES AS WELL.EXPECTS TO HAVE PROGRAMMES IN OTHER COUNTRIES UNDERWAY IN MAJORITY OF ITS MARKETS BY END OF SEPTEMBER 2021.COMPANY INTENDS TO COMPLETE REPAIR AND REPLACEMENT PROGRAMS WITHIN APPROXIMATELY 12 MONTHS..

Philips Announces Partnership With Bento

Aug 31 (Reuters) - Koninklijke Philips NV <PHG.AS>::ANNOUNCES PARTNERSHIP WITH BENTO.PARTNERSHIP WITH BENTO TO ENABLE DENTAL PRACTICES, EMPLOYERS, AND GROUPS TO BUNDLE PHILIPS ORAL CARE PRODUCTS INTO DENTAL BENEFIT PLANS.

FDA Says Philips Respironics Recalls V60 And V60 Plus Ventilators Due To Risk Of Receiving Reduced Oxygen

Aug 3 (Reuters) - FDA::FDA - PHILIPS RESPIRONICS RECALLS V60 AND V60 PLUS VENTILATORS EQUIPPED WITH HIGH FLOW THERAPY SOFTWARE VERSIONS 3.00 AND 3.10.FDA - HAS IDENTIFIED THIS AS A CLASS I RECALL FOR PHILIPS RESPIRONICS.FDA - PHILIPS RESPIRONICS RECALLS V60 AND V60 PLUS VENTILATORS DUE TO RISK OF RECEIVING REDUCED OXYGEN.

Philips Aims To Ramp Up Repair Kit Capacity To 80,000/Week By Start Of Q4

July 26 (Reuters) - Koninklijke Philips NV <PHG.AS> in a conference call::CANNOT PREDICT HOW LONG FDA APPROVAL ON REPAIRS WILL TAKE, EXPERIENCE SUGGESTS 8-WEEK APPROXIMATE TIMELINE COULD BE EXPECTED.CO HAS PLACED REPAIR STOCKS IN WAREHOUSES IN SOME COUNTRIES SO IT CAN MOVE QUICKLY.FDA HAS ASKED CO TO PROVIDE DATA THAT THE REPLACEMENT MATERIAL IS SAFE AND SOUND.RAMPING UP CAPACITY FOR REPAIR KITS FROM 30,000 TO 55,000 A WEEK AT START OF Q3, AIMING FOR 80,000 BY START OF Q4.IF SUPPLIERS CAN RAMP UP FASTER, CO AIMS TO SHORTEN EXPECTED 12-MONTH THOROUGHPUT TIME.ON THE FOAM, WHEN DREAMSTATION 1 WAS RELEASED, IT WAS TESTED AGAINST ALL THE STANDARDS IN PLACE, INCLUDING VOC STANDARDS AT THAT TIME.WE HAVE NOT DETECTED TDI OR TDA IN THE SAMPLES TESTED IN THE LAB, FURTHER RESEARCH IS ONGOING.WHEN NEW VOC STANDARD CAME OUT IN JUNE 2018, DID NOT HAVE A SAFETY CONCERN.TOO EARLY TO CONCLUDE THE GASES HAVE A SEVERE HEALTH IMPACT, WE TOOK AN INITIAL WORST-CASE APPROACH .WE HAVE INITIATED A MUCH WIDER SAMPLE OF TESTING, HAVE ALSO ASKED MULTIPLE LABS TO DO THE TESTING.ESTIMATES PROPORTION OF REPAIR/REPLACE AT REPLACE 2/3, REPAIR 1/3.ON HOSPITALS/COVID: ELECTIVE PROCEDURES ARE BACK, HOSPITAL FINANCES ARE IMPROVING, BACKSTOPS ARE BEING PUT IN PLACE, SO WE HAVE SEEN STRONG WILLINGNESS TO INVEST.SHARE BUYBACK LEAVES PLENTY OF ROOM FOR FURTHER ACQUISITIONS AND BOLT-ONS.WE HAVE NOT INCLUDED ANY PROVISION FOR LEGAL CASES, NOT ABLE TO MAKE REASONABLE ESTIMATE AT THIS STAGE.Further company coverage: PHG.AS.

Philips Q2 Adj. EBITA Up At EUR 532 Mln, Above Expectations

July 26 (Reuters) - Koninklijke Philips NV <PHG.AS>::PHILIPS DELIVERS Q2 SALES OF EUR 4.2 BILLION, WITH 9% COMPARABLE SALES GROWTH; NET INCOME AMOUNTS TO EUR 153 MILLION AND ADJUSTED EBITA MARGIN IMPROVES 280 BASIS POINTS TO 12.6%; COMPANY ANNOUNCES EUR 1.5 BILLION SHARE BUYBACK PROGRAM.Q2 OPERATING CASH FLOW AMOUNTED TO EUR 332 MILLION, COMPARED TO EUR 446 MILLION IN Q2 2020.OUTLOOK REMAINS WITHIN OUR GUIDED RANGE, WITH LOW-TO-MID-SINGLE-DIGIT COMPARABLE SALES GROWTH AND AN ADJUSTED EBITA MARGIN IMPROVEMENT OF 60 BASIS POINTS EXPECTED FOR GROUP IN 2021.Q2 FREE CASH FLOW WAS EUR 167 MILLION, COMPARED TO EUR 212 MILLION IN Q2 2020.Q2 ADJUSTED EBITA INCREASED TO EUR 532 MILLION, OR 12.6% OF SALES, COMPARED TO EUR 390 MILLION, OR 9.8% OF SALES, IN Q2 2020.IN Q2, PRODUCTIVITY SAVINGS AMOUNTED TO EUR 90 MILLION, OF WHICH PROCUREMENT SAVINGS AMOUNTING TO EUR 44 MILLION, AND SAVINGS OF EUR 46 MILLION DELIVERED BY OVERHEAD AND OTHER PROGRAMS.RE PRODUCT RECALL: PHILIPS HAS TAKEN A PROVISION OF EUR 250 MILLION IN Q2 OF 2021.WE ARE LAUNCHING A NEW SHARE BUYBACK PROGRAM OF EUR 1.5 BILLION IN LINE WITH OUR BALANCED CAPITAL ALLOCATION POLICY.EXPECTS TO START PROGRAM IN Q3 OF 2021 AND TO COMPLETE IT WITHIN THREE YEARS.

Philips Receives FDA BDD For Laser-Assisted IVC Filter Removal Device

July 21 (Reuters) - KONINKLIJKE PHILIPS NV <PHG.AS>::PHILIPS RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION FOR LASER-ASSISTED IVC FILTER REMOVAL DEVICE.FDA BREAKTHROUGH DEVICE DESIGNATION IS GRANTED TO NOVEL MEDICAL DEVICES THAT HAVE THE POTENTIAL TO PROVIDE MORE EFFECTIVE TREATMENT.IT IS ESTIMATED THAT IN THE UNITED STATES MORE THAN ONE MILLION PATIENTS WITH INFERIOR VENA CAVA (IVC) FILTERS WOULD BENEFIT FROM FILTER REMOVAL TO REDUCE THE RISK OF LONG-TERM COMPLICATIONS.LASER FOR IVC FILTER REMOVAL IS INTENDED TO SAFELY ABLATE TISSUE TO REMOVE EMBEDDED FILTERS.LIMITED OPTIONS EXIST FOR EMBEDDED IVC FILTER REMOVAL, AND INDEPENDENT STUDIES INDICATE HIGH SUCCESS RATES USING A PHILIPS EXCIMER LASER SHEATH.UNDER THE PROGRAM, THE FDA WILL PROVIDE PHILIPS WITH PRIORITY REVIEW AND INTERACTIVE COMMUNICATION REGARDING DEVICE DEVELOPMENT THROUGHOUT THE SUBMISSION PROCESS.

Philips, Cognizant Partner On Digital Health Solutions

July 8 (Reuters) - Koninklijke Philips NV <PHG.AS>::PHILIPS AND COGNIZANT COLLABORATE TO INTRODUCE DIGITAL HEALTH SOLUTIONS TO PROVIDERS, RESEARCHERS, AND PATIENTS.

Philips Partners With NICO.LAB For Stroke Diagnosis and Treatment

July 7 (Reuters) - KONINKLIJKE PHILIPS NV <PHG.AS>::ACCELERATES STROKE DIAGNOSIS AND TREATMENT WITH EXPANDED INTEGRATED SOLUTIONS AND STRATEGIC PARTNERSHIP.NEW COLLABORATION WITH NICO.LAB.

Philips Announces First Patient Treated With Its New Real-Time 3D Intracardiac Echocardiography Catheter – VeriSight Pro

July 1 (Reuters) - KONINKLIJKE PHILIPS NV <PHG.AS>::PHILIPS ANNOUNCES FIRST PATIENT TREATED WITH ITS NEW REAL-TIME 3D INTRACARDIAC ECHOCARDIOGRAPHY CATHETER – VERISIGHT PRO.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up